(S)-(+)-3-Quinuclidinol CAS 34583-34-1 Purity ≥99.0% Factory High Quality

Chemical Name: (S)-(+)-3-Quinuclidinol CAS: 34583-34-1 Appearance: Off-White to White Crystalline Powder Purity: ≥99.0% Assay: 98.0%~102.0% (on Anhydrous Basis) Intermediate of API (CAS: 242478-38-2) in the treatment of Overactive Bladder (Pollakiuria) Enquiry: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light & moistureCommercial Supply Related Intermediates:  CAS: 242478-38-2 (R)-(-)-3-Quinuclidinol CAS: 25333-42-0 (S)-(+)-3-Quinuclidinol CAS: 34583-34-1 3-Quinuclidinone Hydrochloride CAS: 1193-65-3 1-Phenyl-1,2,3,4-Tetrahydro-Isoquinoline CAS: 22990-19-8 (S)-1-Phenyl-1,2,3,4-Tetrahydroisoquinoline CAS: 118864-75-8
Item Specifications
Appearance Off-White to White Crystalline Powder
Identification IR Specturm Conforms to Reference Spectrum
Specific Rotation [α]D20 44.0°±2.0°
Loss On Drying ≤0.50%
Purity ≥99.0%
Assay 98.0%~102.0% (on Anhydrous Basis)
Test Standard Enterprise Standard
Usage Chiral Compounds; Pharmaceutical Intermediates

Description:

Specifications:

Package & Storage:

Chemical Name (S)-(+)-3-Quinuclidinol
Synonyms (S)-Quinuclidin-3-ol 
CAS Number 34583-34-1
CAT Number RF-CC118
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C7H13NO
Molecular Weight 127.18
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (S)-(+)-3-Quinuclidinol (CAS: 34583-34-1) with high quality, widely used in synthesis of pharmaceutical intermediates and active pharmaceutical ingredient (API). (S)-(+)-3-Quinuclidinol is an intermediate in the synthesis of API (CAS: 242478-38-2). (CAS: 242478-38-2) is an antimuscarinic medication that is used to treat an overactive bladder causing symptoms of frequency, urgency, or incontinence. It is an M3 muscarinic receptor antagonist that was developed and launched for the treatment of overactive bladder (pollakiuria) in Europe. M3 receptors have been implicated in neurally evoked smooth muscle contractions of the bladder, and M2 receptors have also been suspected of playing a role because of their dominance in the detrusor muscle.  

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours